Skandinaviska Enskilda Banken AB publ Makes New Investment in Dyne Therapeutics, Inc. (NASDAQ:DYN)

Skandinaviska Enskilda Banken AB publ purchased a new stake in shares of Dyne Therapeutics, Inc. (NASDAQ:DYN) in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The fund purchased 26,816 shares of the company’s stock, valued at approximately $634,000.

Several other large investors have also made changes to their positions in DYN. Bank of New York Mellon Corp raised its position in Dyne Therapeutics by 0.3% during the fourth quarter. Bank of New York Mellon Corp now owns 234,798 shares of the company’s stock valued at $5,532,000 after acquiring an additional 698 shares in the last quarter. KBC Group NV raised its holdings in shares of Dyne Therapeutics by 53.4% during the 3rd quarter. KBC Group NV now owns 2,157 shares of the company’s stock valued at $77,000 after purchasing an additional 751 shares in the last quarter. Quantbot Technologies LP bought a new position in shares of Dyne Therapeutics during the 3rd quarter valued at $34,000. Virtue Capital Management LLC boosted its holdings in Dyne Therapeutics by 4.4% in the third quarter. Virtue Capital Management LLC now owns 23,208 shares of the company’s stock worth $834,000 after purchasing an additional 981 shares in the last quarter. Finally, Point72 DIFC Ltd bought a new stake in Dyne Therapeutics in the third quarter worth $36,000. Institutional investors own 96.68% of the company’s stock.

Insiders Place Their Bets

In other Dyne Therapeutics news, insider Oxana Beskrovnaya sold 2,598 shares of the firm’s stock in a transaction dated Tuesday, February 18th. The shares were sold at an average price of $13.95, for a total transaction of $36,242.10. Following the completion of the transaction, the insider now owns 199,087 shares in the company, valued at $2,777,263.65. This trade represents a 1.29 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Insiders have sold 6,237 shares of company stock worth $77,760 over the last 90 days. Corporate insiders own 20.77% of the company’s stock.

Dyne Therapeutics Stock Up 2.2 %

DYN stock opened at $12.31 on Tuesday. The business’s 50-day simple moving average is $14.33 and its 200 day simple moving average is $24.90. The company has a market cap of $1.39 billion, a PE ratio of -3.46 and a beta of 1.11. Dyne Therapeutics, Inc. has a twelve month low of $11.18 and a twelve month high of $47.45.

Dyne Therapeutics (NASDAQ:DYN) last released its quarterly earnings data on Tuesday, March 4th. The company reported ($0.88) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.92) by $0.04. On average, equities research analysts anticipate that Dyne Therapeutics, Inc. will post -3.44 EPS for the current year.

Wall Street Analysts Forecast Growth

Several research firms have recently issued reports on DYN. Chardan Capital reiterated a “buy” rating and set a $50.00 price target on shares of Dyne Therapeutics in a research note on Monday. Raymond James raised Dyne Therapeutics to a “strong-buy” rating in a research report on Thursday, December 12th. Piper Sandler dropped their price target on shares of Dyne Therapeutics from $53.00 to $48.00 and set an “overweight” rating on the stock in a research report on Friday, February 28th. Baird R W raised shares of Dyne Therapeutics to a “strong-buy” rating in a report on Thursday, December 12th. Finally, Robert W. Baird began coverage on shares of Dyne Therapeutics in a research note on Friday, December 13th. They issued an “outperform” rating and a $46.00 target price on the stock. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating, twelve have given a buy rating and two have issued a strong buy rating to the company’s stock. According to data from MarketBeat, Dyne Therapeutics has a consensus rating of “Moderate Buy” and a consensus price target of $48.85.

Dyne Therapeutics Company Profile

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.